ECONOMIC IMPACT OF CANCER-RELATED PRODUCTIVITY LOSSES IN HIGH-INCOME AND MIDDLE-INCOME ASIA-PACIFIC MARKETS: TRENDS FROM 2010 TO 2022
Author(s)
Manoj Gambhir, PhD1, Athar Hasan Siddiqui, MSc2, Anne Meiwald, MSc3, Chamath Perera, MSc2, Aimee Fox, PhD2, Sameer B. Gokhale, MBA, MS4;
1Seek ltd, Port melbourne, Australia, 2Adelphi Values PROVE, Bollington, United Kingdom, 3Adelphi Values, Bollington, United Kingdom, 4MSD Healthcare Pvt. Ltd., Director, Value & Implementation Outcomes Research Asia Pacific Region, Mumbai, India
1Seek ltd, Port melbourne, Australia, 2Adelphi Values PROVE, Bollington, United Kingdom, 3Adelphi Values, Bollington, United Kingdom, 4MSD Healthcare Pvt. Ltd., Director, Value & Implementation Outcomes Research Asia Pacific Region, Mumbai, India
OBJECTIVES: Cancer imposes a significant health and economic burden across the Asia-Pacific region, with notable disparities between markets. This study estimates productivity losses attributable to mortality and morbidity from five high-burden cancers based on year 2022: tracheal, bronchus and lung; stomach; colorectal; breast; and cervical across high-income markets (HIMs) and middle-income markets (MIMs) at four time points: 2010, 2015, 2019, and 2022.
METHODS: HIMs included Australia, Hong Kong, Japan, New Zealand, Singapore, South Korea, and Taiwan; MIMs comprised India, Indonesia, Malaysia, Philippines, Thailand, and Vietnam. Data on deaths, Years of Life Lost (YLL), and Years Lived with Disability (YLD) were sourced from the Institute for Health Metrics and Evaluation. Productivity metrics: Years of Productive Life Lost (YPLL), Present Value of Future Lost Productivity (PVFLP), Productive YLD (PYLD), and Value of YLD (VYLD) were calculated using market-specific parameters (retirement age, wages, labor force participation, unemployment). Temporal trends were assessed using linear regression.
RESULTS: In HIMs, cancer-related deaths increased from 411,651 in 2010 to 468,480 in 2022 (14%). YLL remained relatively stable, while PVFLP declined from $12.3 billion to $10.1 billion. YLD rose from 466,498 to 553,782, whereas VYLD remained consistent ($3.0 to $2.9 billion). In MIMs, deaths rose substantially from 753,961 in 2010 to 1,113,815 in 2022 (48%). YLL increased from 24,615,518 to 35,018,065, and YLD from 436,749 to 750,609. PVFLP grew from $2.6 billion to $3.2 billion, while VYLD increased from $238.1 million to $360.3 million. Regression analysis indicated a decline in YLL per death across both income groups. YLD per incident case decreased in HIMs but showed an upward trend in MIMs.
CONCLUSIONS: The gap between HIMs and MIMs is widening, with MIMs experiencing disproportionately higher morbidity and productivity losses due to cancer. Targeted investment in prevention, early detection, and equitable access to effective treatment is essential to improve health and economic outcomes.
METHODS: HIMs included Australia, Hong Kong, Japan, New Zealand, Singapore, South Korea, and Taiwan; MIMs comprised India, Indonesia, Malaysia, Philippines, Thailand, and Vietnam. Data on deaths, Years of Life Lost (YLL), and Years Lived with Disability (YLD) were sourced from the Institute for Health Metrics and Evaluation. Productivity metrics: Years of Productive Life Lost (YPLL), Present Value of Future Lost Productivity (PVFLP), Productive YLD (PYLD), and Value of YLD (VYLD) were calculated using market-specific parameters (retirement age, wages, labor force participation, unemployment). Temporal trends were assessed using linear regression.
RESULTS: In HIMs, cancer-related deaths increased from 411,651 in 2010 to 468,480 in 2022 (14%). YLL remained relatively stable, while PVFLP declined from $12.3 billion to $10.1 billion. YLD rose from 466,498 to 553,782, whereas VYLD remained consistent ($3.0 to $2.9 billion). In MIMs, deaths rose substantially from 753,961 in 2010 to 1,113,815 in 2022 (48%). YLL increased from 24,615,518 to 35,018,065, and YLD from 436,749 to 750,609. PVFLP grew from $2.6 billion to $3.2 billion, while VYLD increased from $238.1 million to $360.3 million. Regression analysis indicated a decline in YLL per death across both income groups. YLD per incident case decreased in HIMs but showed an upward trend in MIMs.
CONCLUSIONS: The gap between HIMs and MIMs is widening, with MIMs experiencing disproportionately higher morbidity and productivity losses due to cancer. Targeted investment in prevention, early detection, and equitable access to effective treatment is essential to improve health and economic outcomes.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE269
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology